Clinical and Experimental Nephrology

, Volume 22, Issue 3, pp 613–619 | Cite as

Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction

  • Aya Imafuku
  • Naoki Sawa
  • Akinari Sekine
  • Masahiro Kawada
  • Rikako Hiramatsu
  • Masayuki Yamanouchi
  • Eiko Hasegawa
  • Noriko Hayami
  • Jyunichi Hoshino
  • Yoshifumi Ubara
  • Kenmei Takaichi
Original article
  • 132 Downloads

Abstract

Background

Ceftriaxone (CTRX) is a known cause of biliary pseudolithiasis (BPL) mainly in children. Biliary elimination of CTRX increases in patients with renal dysfunction. However, the influence of renal dysfunction on the incidence of CTRX-associated BPL has not been well investigated. The aim of this study was to investigate the cumulative incidence of CTRX-associated BPL in adults and to assess if renal dysfunction is a risk factor.

Methods

We retrospectively analyzed the medical records of 478 patients treated with CTRX to assess the incidence and risk factors of CTRX-associated BPL. We examined age, sex, body weight, dosage, and duration of CTRX therapy, and the concentrations of serum creatinine, estimated glomerular filtration rate (eGFR), albumin, and serum calcium in all the patients. The cumulative incidence of BPL was calculated using a competing risk model. The multivariate analysis of each variable for the development of BPL was assessed by a Cox proportional hazards model.

Results

A total of 362 patients (75.7%) had renal dysfunction (eGFR: < 60 mL/min). The cumulative incidence of BPL in patients with renal dysfunction was significantly higher than that in patients with normal kidney function (4.1 vs. 0.6%, p = 0.017). Renal dysfunction (Hazard ratio (HR) 8.14, 95% CI 1.05–63.0, p = 0.045) and female sex (HR 5.35, 95% CI 1.17–24.5, p = 0.031) were independent risk factors of CTRX-associated BPL, which was confirmed using multivariate analysis (renal dysfunction: HR 7.93, 95% CI 1.04–60.5, p = 0.046) (female sex HR 4.65, 95% CI 1.03–21.1, p = 0.046).

Conclusions

Renal dysfunction is an independent risk factor of CTRX-associated BPL in adults.

Keywords

Ceftriaxone-associated biliary pseudolithiasis Kidney dysfunction Infection 

Notes

Acknowledgements

This study was funded by the Okinaka Memorial Institute for Medical Research.

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB Approval Number 994) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982;10:207–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.CrossRefPubMedGoogle Scholar
  3. 3.
    Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99:1772–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5:708–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2:1411–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322:141–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 1999;88:1352–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Palanduz A, Yalcin I, Tonguc E, Guler N, Ones U, Salman N, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2000;28:166–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Ozturk A, Kaya M, Zeyrek D, Ozturk E, Kat N, Ziylan SZ. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol. 2005;46:112–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006;34:217–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996;19:50–4.PubMedGoogle Scholar
  13. 13.
    Soysal A, Erasov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49:404–7.PubMedGoogle Scholar
  14. 14.
    Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet. 1989;2:165.CrossRefPubMedGoogle Scholar
  15. 15.
    Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34:1146–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cometta A, Gallot-Lavallee-Villars S, Iten A, Cantoni L, Anderegg A, Gonvers JJ, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother. 1990;25:689–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Becker CD, Fischer RA. Acute cholecystitis caused by ceftriaxone stones in an adult. Case Rep Med. 2009;2009:132452.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 1991;86:1251–4.PubMedGoogle Scholar
  19. 19.
    Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25:1389–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E. Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther. 1983;33:633–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int. 2004;46:322–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Sasaki Y, Aoki S, Aoki K, Achiwa K, Yama T, Kubota M, et al. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. Nihon Shokakibyo Gakkai Zasshi. 2009;106:569–75.PubMedGoogle Scholar
  23. 23.
    Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am J Med. 1984;77:26–32.PubMedGoogle Scholar
  24. 24.
    Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983;24:529–32.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rivera M, Garcia-Herrera AL, Burguera V, Sosa-Barrios H, Palomares JR, Quereda C. Ceftriaxone-associated gallbladder pseudolithiasis in a PD patient. Perit Dial Int. 2011;31:97–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kutuya N, Ozaki Y, Okazaki T. A symptomatic child with ceftriaxone-associated biliary pseudolithiasis. J Med Ultrason. 2008;35:125–8.CrossRefGoogle Scholar
  27. 27.
    Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics. 1996;98:133–5.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  • Aya Imafuku
    • 1
  • Naoki Sawa
    • 1
    • 2
  • Akinari Sekine
    • 1
  • Masahiro Kawada
    • 1
  • Rikako Hiramatsu
    • 1
  • Masayuki Yamanouchi
    • 1
  • Eiko Hasegawa
    • 1
  • Noriko Hayami
    • 1
  • Jyunichi Hoshino
    • 1
  • Yoshifumi Ubara
    • 1
  • Kenmei Takaichi
    • 1
  1. 1.Department of Nephrology CenterToranomon HospitalMinatokuJapan
  2. 2.Okinaka Memorial Institute for Medical ResearchMinatokuJapan

Personalised recommendations